ArticleBMC microbiology2025
Probiotic attributes, antioxidant and neuromodulatory effects of GABA-Producing Lactiplantibacillus plantarum SY1 and optimization of GABA production.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Probiotic Bacteria in Stimulating Human Physiological Responses: Metabolic Function and Overall Health.Foods (Basel, Switzerland) · 2026Review
- Multifactorial Neuroprotective Potential of γ-Aminobutyric acid-Producing Potential Probiotics Against Stress Induced Neuronal Cell Lines.Probiotics and antimicrobial proteins · 2026Article
- GABA-Producing Bacteria as Potential Psychobiotics in Gut-Brain Axis Regulation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Γ-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the central nervous system, has been shown to alleviate various physiological disorders including insomnia, hypertension, depression, and memory loss. Lactic acid bacteria (LAB), recognized as safe GABA producers, have attracted increasing attention. This study aimed to screen GABA-producing LAB from naturally fermented dairy products and evaluate their probiotic potential, antioxidant and neuromodulatory activities, while optimizing GABA production. GABA-producing LAB were screened using the Berthelot method and thin-layer chromatography. The safety of Lactiplantibacillus plantarum SY1 was assessed through hemolysin production and drug sensitivity tests. L. plantarum SY1 demonstrated high tolerance to acidic conditions and low bile salt concentrations, along with significant antioxidant capacity (49 ± 0.2% DPPH radical scavenging rate, 86.1 ± 0.14% hydroxyl radical scavenging rate, and 32.7 ± 1.6% superoxide radical anion scavenging rate). In vivo experiments revealed that L. plantarum SY1 extended the lifespan of C. elegans N2, enhanced oxidative stress resistance, and delayed paralysis in transgenic C. elegans (CL4176) by 23.53%. Through OFAT strategy and RSM optimization, GABA production reached 1.49 g/L under optimal conditions (37℃, pH 4.44, 96 h fermentation, and 4.16% inoculum). These findings demonstrate that L. plantarum SY1 is a promising GABA-producing strain with antioxidant and neuromodulatory effects, suggesting its potential as an anti-aging and neuroprotective probiotic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.